The approval of GLP-1 RAs, starting with exenatide in 2005, followed by semaglutide and oral formulations, has expanded treatment options for patients seeking effective, long-term solutions for T2DM and obesity (15)
Consent for publication This is a review article not involving studies on human subjects and obtaining a consent to publish is not required
Metabolic syndromes can increase a persons risk of cardiovascular disease, stroke and type 2 diabetes
On the global spectrum, model Winnie Harlow has made it her mission to represent women living with skin conditions
Each peptide in the Repair & Glow protocol targets a different part of the healing and regeneration process
Interestingly, however, common responses to GLP1/E were observed in both PCOS models, with upregulation of hypothalamic pathways involved in autophagy and vesicle-mediated transport, and downregulation of pathways primarily related to the immune system